Cannabis for COVID: Israel Pioneers Research into Treatment Options
Ryan Allway
June 11th, 2020
App, Exclusive, News, Top Story
The COVID-19 crisis has brought the global economy to a grinding halt and impacted nearly every walk of life. With so much hanging in the balance, biotech and pharmaceutical companies around the globe have been rapidly searching for vaccines and treatment options. Researchers in Israel believe that cannabis-derived products could treat patients with COVID-19 and they’re working on at least three treatment candidates.
Let’s take a look at these treatment options and how the move could further solidify Israel’s status as a leader in cannabinoid science.
COVID-19 Treatment Candidates
InnoCan Pharma is collaborating with Tel Aviv University to create a COVID-19 treatment from cannabidiol, or CBD, loaded exosomes. These small structures are attached to cells and responsible for cellular communication and the delivery of macromolecules between cells. Researchers believe that the anti-inflammatory effects of CBD could help aid the recovery of infected lung cells when administered through an inhalation technique.
The second research group is investigating a treatment that combines CBD with steroids. Over the course of a few weeks, researchers will trial the treatment on ten patients with COVID-19 that are receiving steroids at Israel’s Rabin Medical Center. If successful, the group will expand the treatment to another 40 patients under conditions set by the U.S. FDA clinical trial regulations and guidelines.
Finally, Tel Aviv’s Ichilov Medical Center is conducting a study to understand whether cannabis’ anti-inflammatory properties may slow down lung infections in those diagnosed with COVID-19. CBD-based treatments are being administered in collaboration with several wards in the hospital. Researchers expect dozens of patients with moderate COVID-19 infections to participate in the trial of safe and non-addictive CBD.
Click here to learn more about investing in the Israeli cannabis market
Solidifying Israel’s Position
Israel is already an established leader in cannabinoid research. In fact, Dr. Raphael Mechoulam—known as the Godfather of Cannabis—discovered tetrahydrocannabinol, or THC, back in the 1960s after asking the police if he could use confiscated cannabis to conduct research. Many Israeli companies have followed in his footsteps to introduce both research breakthroughs and innovative new strains and medical devices to market.
Earlier this year, the country finalized plans to permit the export of medical cannabis beginning in mid-June. The move could establish the country as a leading supplier of cannabis to Europe, Asia and other global markets given its unique climate that’s ideal for cannabis cultivation and its proximity to so many emerging end markets. These dynamics come in addition to its healthy domestic demand for cannabis.
Click the image below to learn more about the cannabis investment opportunity in Israel
Several companies have already applied for licenses to export medical cannabis, but Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF) is one of the only pure-plays in the space. The company has a fully-funded 230,000 sq. ft. hybrid greenhouse cultivation project and partnership with a late-stage project consisting of about 200,000 sq. ft. of greenhouses located on 880,000 sq. ft. of agricultural land.
In addition to cultivation, the company has already partnered with leading Israeli research institutions and universities to leverage their expertise and bring novel products to market that differentiate them from other producers of raw medical cannabis. These dynamics could result in higher-margin medical products and the creation of long-term shareholder value.
Click here to learn more about investing in the Israeli cannabis market
Looking Ahead
Israel continues to lead the way when it comes to cannabinoid research, including in the research for treatments to COVID-19. In addition, the country’s new export laws could transform it into a leading supplier of medical cannabis to nearby end markets, including Europe and Asia. The European market alone is projected to be worth double that of Canada and the U.S. with its 740 million residents.
Learn more about Isracann Biosciences by visiting their website or downloading their investor presentation.
Disclaimer
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
JWC is a Licensed Producer under the ACMPR with the goal of helping patients by providing clean, consistent medical cannabis products.
NexTech AR Solutions is bringing augmented reality and holographic teleportation to the cannabis market and other fast-growing markets by turning 2D products into exciting 3D consumer experiences.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
